Quarterly Result14 Oct 2025, 04:41 pm
Thyrocare Technologies Reports 22% YoY Revenue Growth in Q2FY26, Declares Interim Dividend and Bonus Shares
AI Summary
Thyrocare Technologies Limited, a leading healthcare diagnostics company, has announced its results for the quarter ended September 30, 2025. The company reported a 22% year-on-year growth in revenue, with a significant increase in Normalized EBITDA, PAT, and Gross Margin. Thyrocare processed 53.3 million tests in Q2FY26, marking a strong 21% year-on-year growth. The company also announced the issuance of bonus shares in the proportion of 2:1 and an interim dividend of INR 7 per equity share. Four new laboratories were added in H1FY26, further strengthening its regional presence and enhancing service accessibility.
Key Highlights
- Revenue of INR 216.53 Cr in Q2-FY26 with a growth of 22% YoY
- Normalized EBITDA, PAT, and Gross Margin significantly increased
- Processed 53.3 million tests in Q2FY26, marking a strong 21% year-on-year growth
- Issuance of bonus shares in the proportion of 2:1
- Interim dividend of INR 7 per equity share